ArticleChemical science2018
Facile chemoenzymatic synthesis of a novel stable mimic of NAD
Article in Chemical science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- NADRSC chemical biology · 2026Review
- The evolving landscape of enzymatic technologies for precision synthesis of antibody-drug conjugates.Antibody therapeutics · 2026Review
- Emerging chemical strategies for CD38 inhibition: restoring NADBioorganic & medicinal chemistry · 2026Review
- Chemical inactivation of a bacterial immune system de-domesticates a temperate phage and promotes its spread.bioRxiv : the preprint server for biology · 2026Article
- Synthesis of Bispecific Conjugates by ADP-Ribosyl Cyclases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- PAR-Driven Condensation Maintains Stalled Replication Fork Stability.bioRxiv : the preprint server for biology · 2026Article
- A versatile platform for chemical engineering of exosomes empowered by ADP-ribosyl cyclases.Nature communications · 2025Article
- Targeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Article
- Article
- ADP-ribosyltransferase-based biocatalysis of nonhydrolyzable NAD+ analogs.The Journal of biological chemistry · 2025Article
- Mono-ADP-Ribosylation of Peptides: An Overview of Synthetic and Chemoenzymatic Methodologies.Chembiochem : a European journal of chemical biology · 2024Review
- An NADTetrahedron · 2024Article
- Article
- Discovery of PARP1-Sparing Inhibitors for Protein ADP-Ribosylation.ACS medicinal chemistry letters · 2024Article
- Nicotinamide Riboside: What It Takes to Incorporate It into RNA.Molecules (Basel, Switzerland) · 2024Review
- Synthesis of site-specific Fab-drug conjugates using ADP-ribosyl cyclases.Protein science : a publication of the Protein Society · 2024Article
- Artificial Small Molecules as Cofactors and Biomacromolecular Building Blocks in Synthetic Biology: Design, Synthesis, Applications, and Challenges.Molecules (Basel, Switzerland) · 2023Review
- The Regulation of Phosphorus Release by Penicillium chrysogenum in Different Phosphate via the TCA Cycle and Mycelial Morphology.Journal of microbiology (Seoul, Korea) · 2023Article
- 4-Thioribose Analogues of Adenosine Diphosphate Ribose (ADPr) Peptides.Organic letters · 2023Article
- A phosphite-based screening platform for identification of enzymes favoring nonnatural cofactors.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Nicotinamide adenine dinucleotide (NAD
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.